2023 Updates: Lilly's Global COVID-19 Response
January 31, 2023 Posted by: Eli Lilly and Company
![article-header 0000 shutterstock 1081663553](http://images.ctfassets.net/srys4ukjcerm/6gB1ATun0aXO1mI4mJ3tfR/6335404bd537e6ef569e4d6caaf484f8/article-header_0000_shutterstock_1081663553.jpg)
For more information about Lilly's COVID-19 therapies authorized for emergency use, contact the Lilly COVID Hotline at 1-855-LillyC19 (1-855-545-5921).
Lilly continues to closely monitor the COVID-19 pandemic and its global impact. As this is an evolving topic, Lilly will include relevant announcements and information on this page.
If the COVID-19 pandemic has impacted your ability to afford or access your Lilly medicine, contact us via these options.
Patients and physicians can visit the U.S. Health & Human Services (HHS) Therapeutics Distribution locator to find a potential treatment location.
Lilly has utilized the full force of its expertise to develop novel antibodies that have helped prevent hospital and death in certain individuals with COVID-19. Lilly’s purpose is to create medicines that make life better across key therapeutic areas, as well as COVID-19.